| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZD6482 | GDSC1000 | pan-cancer | AAC | 0.034 | 0.3 |
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | 0.17 | 0.3 |
| mRNA | BRD-K27224038 | CTRPv2 | pan-cancer | AAC | 0.07 | 0.3 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.05 | 0.3 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | -0.072 | 0.3 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | 0.06 | 0.3 |
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | -0.031 | 0.3 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | -0.056 | 0.3 |
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | 0.059 | 0.3 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.033 | 0.3 |